A recent study published in JAMA Network Open evaluated the cost-effectiveness of monoclonal antibodies (mAbs) as pre-exposure prophylaxis (PrEP) for coronavirus disease 2019 (COVID-19). Study: Health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results